Day: November 29, 2021

Analysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study population Analysis was conducted in response to US Food and Drug Administration (FDA) request for additional clinical data on effect of ZYESAMI compared to currently-approved therapy including remdesivir NRx to submit new analysis and safety data to the FDA in support of Emergency Use Authorization and Breakthrough Therapy Designation Requests US National Institutes of Health-sponsored trial to compare effects of ZYESAMI and remdesivir individually and in combination continues to enroll patientsRADNOR, Pa., Nov. 29, 2021 (GLOBE NEWSWIRE) — NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has completed an analysis to identify...

Sports Fans Can Now Access Origin Sports on Samsung TV Plus and The Roku Channel CHARLOTTE, Nov. 29, 2021 (GLOBE NEWSWIRE) —  Origin Sports Network has expanded its lineup of distribution partners to include The Roku® Channel (Ch. 238, U.S.-only) and Samsung TV Plus (Ch. 1163), more than quadrupling its addressable audience size.   A 24/7 linear streaming network, Origin Sports brings viewers unique content featuring Hall of Famers, All-Americans, All-Stars, No. 1 picks and National Champions before they became household names. Leveraging Raycom’s more than four decades of award-winning production expertise, Origin Sports launched in July with distribution on The Roku® Channel in Canada and on XUMO (Ch. 713) in the United States, along with YouTube, Facebook, Twitter and Instagram. Pairing nostalgic throwback content with original...

ST. JOHN’S, Newfoundland, Nov. 29, 2021 (GLOBE NEWSWIRE) — Kraken Robotics Inc. (TSX-V: PNG, OTCQB: KRKNF), Canada’s Ocean Company, announced it has filed its financial results for the quarter ended September 30, 2021. Additional information concerning the Company, including its consolidated financial statements and related management’s discussion and analysis (“MD&A”) for the quarter ended September 30, 2021, can be found at www.sedar.com. Unless otherwise stated, all dollar amounts are Canadian dollar denominated. 2021 Financial Guidance Remains UnchangedWe continue to expect revenue for the year ended December 31, 2021, to be $28 million to $30 million, an increase of more than 130% as compared to $12 million in 2020. The forecasted growth is driven by initial deliveries of KATFISH™ 180 towed sonars and Autonomous Launch...

POMPANO BEACH, Fla., Nov. 29, 2021 (GLOBE NEWSWIRE) — In 2020, Land ‘N’ Sea, a division of Mercury Marine and Brunswick Corporation (NYSE:BC) introduced its “Buy with Confidence” virtual program during the height of the COVID-19 pandemic, hosting its shows including the annual Kellogg/Land ‘N’ Sea show virtually and reporting a 40 percent increase in sales compared with their in-person shows in 2019. This year, Land ‘N’ Sea returned to an in-person event at the Mohegan Sun Expo Center in Connecticut while retaining a digital experience for their other shows, and just reported an additional 30% increase in sales over last year’s record show season. Additionally, in-person attendance increased almost 20% compared with the last physical show in Connecticut in ’19. LNS also hosted two additional shows virtually this year, both with...

VANCOUVER, British Columbia, Nov. 29, 2021 (GLOBE NEWSWIRE) — Treatment.com International Inc. (“Treatment” or the “Company”) (CSE: TRUE), (OTC: TREIF), a healthcare AI technology company, has expanded the reach of its Global Library of Medicine (GLM) by adding more members based in Belgium. Treatment’s GLM is the world’s most advanced medical database, and the platform for a new category of tools in global healthcare delivery. The Global Library of Medicine’s consortium of doctors includes more than 50 members across four continents, now including representatives from Europe. “The continued expansion of the Global Library of Medicine’s network of doctors means that the development of our AI-driven database of medical knowledge has a global perspective, positioning Treatment as the solution of choice to the problem of delivering...

FDA Pre-Approval Inspection Identified Deficiencies with the Facility of the Drug Product Manufacturer, Which Require Resolution Prior to PEDMARK Approval RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that it expects to receive a Complete Response Letter (CRL) after the PDUFA target action date of November 27, 2021 from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for PEDMARKTM (a unique formulation of sodium thiosulfate), for intravenous administration for the prevention of ototoxicity associated with cisplatin chemotherapy in pediatric patients ≥1 month to 18 years of age with localized, non-metastatic, solid tumors. The FDA has indicated that, following a recent completion of a pre-approval...